18F-DOPA for Parkinson's Disease

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Parkinson's Disease+5 More18F-DOPA - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at using 18F-DOPA PET/CT imaging in specific patient populations to see if it can help optimize images and identify gallbladder activity patterns.

Eligible Conditions
  • Parkinson's Disease
  • Neuroblastoma
  • Congenital Hyperinsulinism
  • Brain Tumor
  • Neuroendocrine Tumors
  • Lewy Body Disease

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: Within 1 month of PET/CT scan

At the time of enrollment
Gallbladder disease questionnaire
Month 1
Assessment of bladder activity
Assessment of bladder activity artifact
Minimum lesion detectability (SUV)
Minimum lesion detectibility (size)
Month 3
Gallbladder activity pattern

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

18F-DOPA injection
1 of 1

Experimental Treatment

800 Total Participants · 1 Treatment Group

Primary Treatment: 18F-DOPA · No Placebo Group · Phase 3

18F-DOPA injectionExperimental Group · 2 Interventions: Furosemide Injection, 18F-DOPA · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Furosemide
FDA approved
18F-DOPA
2017
Completed Phase 3
~2080

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: within 1 month of pet/ct scan

Who is running the clinical trial?

University of AlbertaLead Sponsor
816 Previous Clinical Trials
375,764 Total Patients Enrolled
Jonathan Abele, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
600 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: